Patients Treated by Radiotherapy With < One Gy to the Brain
Conditions
Brief summary
Context: Studies that address specifically the neurocognitive consequences that can be caused by low-dose radiation receiving during the childhood have still to be performed. In this issue, we focus on an investigation with patients who have received radiotherapy for a benign tumor (skin hemangioma), in France. Patients and methods: More than 8300 children with a skin hemangioma were treated at Gustave Roussy (Île-de-France) from 1941 to 1973 and a number of them have received radiotherapy. These patients have been treated and followed by Gustave Roussy, so their clinical records can be tracked with great accuracy and the ionizing radiation dose to the brain have been estimated. From this patient cohort, the aim is to evaluate neurocognitive dysfunction or disorder that can be caused by low-dose radiation to the brain (less than one Gray (Gy)). A total of 150 patients is expected. They will be contacted by letter to explain the purpose and methods of carrying out tests. Two groups will be analysed according to the received ionizing radiation dose to the brain during the radiotherapy (exposed: 0.05 to 1 Gy, vs unexposed: less than 0.05 Gy). Tests exploring several cognitive functions (memory, arithmetic, orientation, etc.) will be used. Expected results: We expect to describe the potential neurocognitive dysfunction or disorder and to identify risk factors and brain structures whose lesions are responsible for the neurocognitive dysfunction or disorder. A therapeutic treatment will be proposed in the eventuality of screening of a neurocognitive dysfunction or disorder.
Detailed description
CogRad is an interventional study designed within the European project called Cognitive and Cerebrovascular Effects Induced by Low Dose Ionizing Radiation (CerebRad). CerebRad is a collaborative European project funded in 2011 within the 7th European Union (EU) framework programme, Nuclear Fission and Radiation Protection. CerebRad aims to identify the potential cognitive and cerebrovascular risks of radiation doses below 100 milliGray (mGy) when delivered to a young child (pre- or postnatally).
Interventions
The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
Sponsors
Study design
Eligibility
Inclusion criteria
* Subject treated by radiotherapy for a skin hemangioma in childhood at Gustave Roussy between 1941 and 1973 and who have received less than 1 Gy of radiation doses in the brain * Inhabitants of Île-de-France * French medical insurance * Good knowledge and understanding of the French language Non-inclusion Criteria * Cerebral hemangioma * Syndrome genetic predisposition * Pregnant woman * Private person of liberty or under guardianship * Radiation dose to the brain greater than 1 Gy during radiotherapy treatment of skin hemangioma * Chemotherapy during skin hemangioma treatment * Inability to undergo counseling for geographical reasons
Exclusion criteria
* Pregnancy * Inability to perform neurocognitive tests battery for medical reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All neurocognitive dysfunction or disorder on adults measured by means of eight tests | Participants will be tested for the duration of hospital stay (half a day).The neurocognitive tests battery will be carry out 56 years on average after exposure to low-dose radiation. | The score to the 8 tests will be correlate with the presence of neurocognitive dysfunction or disorder |
Countries
France
Contacts
Gustave Roussy, France
Institut National de la Santé Et de la Recherche Médicale, France